Myocardial Infarction – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Myocardial Infarction – Pipeline Review, H2 2016’, provides an overview of the Myocardial Infarction pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Myocardial Infarction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myocardial Infarction and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Myocardial Infarction

The report reviews pipeline therapeutics for Myocardial Infarction by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Myocardial Infarction therapeutics and enlists all their major and minor projects

The report assesses Myocardial Infarction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Myocardial Infarction

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Myocardial Infarction

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Myocardial Infarction pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Amarantus Bioscience Holdings, Inc.

Asterias Biotherapeutics, Inc.

AstraZeneca Plc

Athersys, Inc.

Bayer AG

Bharat Biotech International Limited

BioCardia, Inc.

Biscayne Pharmaceuticals, Inc.

Capricor Therapeutics, Inc.

CellProthera

Celyad SA

Chrysalis BioTherapeutics, Inc.

Compugen Ltd.

CSL Limited

Cynata Therapeutics Limited

Diffusion Pharmaceuticals Inc.

FibroGen, Inc.

Hemostemix Ltd

Hope Pharmaceuticals, Inc.

Human Stem Cells Institute

HUYA Bioscience International, LLC

Inotrem S.A.

Juventas Therapeutics, Inc.

Laboratoires Pierre Fabre SA

Lee's Pharmaceutical Holdings Limited

LegoChem Biosciences, Inc

LG Life Science LTD.

Medestea Research & Production S.p.A.

Mesoblast Limited

miRagen Therapeutics, Inc.

Moderna Therapeutics Inc

Navya Biologicals Pvt Ltd

NeuroVive Pharmaceutical AB

New World Laboratories, Inc.

Novartis AG

NuvOx Pharma LLC

Omeros Corporation

Opsona Therapeutics Limited

Otsuka Holdings Co., Ltd.

Pfizer Inc.

Pharmathen Pharmaceuticals S.A.

Primary Peptides, Inc.

Quantum Genomics SA

Quark Pharmaceuticals, Inc.

Recardio GmbH

RegeneRx Biopharmaceuticals, Inc.

Serodus ASA

Silver Creek Pharmaceuticals, Inc.

Stealth BioTherapeutics Inc.

Stemedica Cell Technologies, Inc.

TaiGen Biotechnology Co., Ltd.

Targazyme, Inc.

The International Biotechnology Center (IBC) Generium

TiGenix NV

Vicore Pharma AB

XBiotech Inc

Yuyu Pharma, Inc.

Zydus Cadila Healthcare Limited

Table of Contents

Table of Contents

Table of Contents 2

Introduction 6

Myocardial Infarction Overview 7

Therapeutics Development 8

Myocardial Infarction - Therapeutics under Development by Companies 10

Myocardial Infarction - Therapeutics under Investigation by Universities/Institutes 15

Myocardial Infarction - Pipeline Products Glance 17

Myocardial Infarction - Products under Development by Companies 21

Myocardial Infarction - Products under Investigation by Universities/Institutes 27

Myocardial Infarction - Companies Involved in Therapeutics Development 29

Myocardial Infarction - Therapeutics Assessment 87

Drug Profiles 104

Myocardial Infarction - Dormant Projects 319

Myocardial Infarction - Discontinued Products 328

Myocardial Infarction - Product Development Milestones 329

Appendix 343

List of Tables

List of Tables

Number of Products under Development for Myocardial Infarction, H2 2016 21

Number of Products under Development for Myocardial Infarction – Comparative Analysis, H2 2016 22

Number of Products under Development by Companies, H2 2016 23

Number of Products under Development by Companies, H2 2016 (Contd..1) 24

Number of Products under Development by Companies, H2 2016 (Contd..2) 25

Number of Products under Development by Companies, H2 2016 (Contd..3) 26

Number of Products under Development by Companies, H2 2016 (Contd..4) 27

Number of Products under Investigation by Universities/Institutes, H2 2016 29

Comparative Analysis by Late Stage Development, H2 2016 30

Comparative Analysis by Clinical Stage Development, H2 2016 31

Comparative Analysis by Early Stage Development, H2 2016 32

Comparative Analysis by Unknown Stage Development, H2 2016 33

Products under Development by Companies, H2 2016 34

Products under Development by Companies, H2 2016 (Contd..1) 35

Products under Development by Companies, H2 2016 (Contd..2) 36

Products under Development by Companies, H2 2016 (Contd..3) 37

Products under Development by Companies, H2 2016 (Contd..4) 38

Products under Development by Companies, H2 2016 (Contd..5) 39

Products under Investigation by Universities/Institutes, H2 2016 40

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 41

Myocardial Infarction – Pipeline by Amarantus Bioscience Holdings, Inc., H2 2016 42

Myocardial Infarction – Pipeline by Asterias Biotherapeutics, Inc., H2 2016 43

Myocardial Infarction – Pipeline by AstraZeneca Plc, H2 2016 44

Myocardial Infarction – Pipeline by Athersys, Inc., H2 2016 45

Myocardial Infarction – Pipeline by Bayer AG, H2 2016 46

Myocardial Infarction – Pipeline by Bharat Biotech International Limited, H2 2016 47

Myocardial Infarction – Pipeline by BioCardia, Inc., H2 2016 48

Myocardial Infarction – Pipeline by Biscayne Pharmaceuticals, Inc., H2 2016 49

Myocardial Infarction – Pipeline by Capricor Therapeutics, Inc., H2 2016 50

Myocardial Infarction – Pipeline by CellProthera, H2 2016 51

Myocardial Infarction – Pipeline by Celyad SA, H2 2016 52

Myocardial Infarction – Pipeline by Chrysalis BioTherapeutics, Inc., H2 2016 53

Myocardial Infarction – Pipeline by Compugen Ltd., H2 2016 54

Myocardial Infarction – Pipeline by CSL Limited, H2 2016 55

Myocardial Infarction – Pipeline by Cynata Therapeutics Limited, H2 2016 56

Myocardial Infarction – Pipeline by Diffusion Pharmaceuticals Inc., H2 2016 57

Myocardial Infarction – Pipeline by FibroGen, Inc., H2 2016 58

Myocardial Infarction – Pipeline by Hemostemix Ltd, H2 2016 59

Myocardial Infarction – Pipeline by Hope Pharmaceuticals, Inc., H2 2016 60

Myocardial Infarction – Pipeline by Human Stem Cells Institute, H2 2016 61

Myocardial Infarction – Pipeline by HUYA Bioscience International, LLC, H2 2016 62

Myocardial Infarction – Pipeline by Inotrem S.A., H2 2016 63

Myocardial Infarction – Pipeline by Juventas Therapeutics, Inc., H2 2016 64

Myocardial Infarction – Pipeline by Laboratoires Pierre Fabre SA, H2 2016 65

Myocardial Infarction – Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016 66

Myocardial Infarction – Pipeline by LegoChem Biosciences, Inc, H2 2016 67

Myocardial Infarction – Pipeline by LG Life Science LTD., H2 2016 68

Myocardial Infarction – Pipeline by Medestea Research & Production S.p.A., H2 2016 69

Myocardial Infarction – Pipeline by Mesoblast Limited, H2 2016 70

Myocardial Infarction – Pipeline by miRagen Therapeutics, Inc., H2 2016 71

Myocardial Infarction – Pipeline by Moderna Therapeutics Inc, H2 2016 72

Myocardial Infarction – Pipeline by Navya Biologicals Pvt Ltd, H2 2016 73

Myocardial Infarction – Pipeline by NeuroVive Pharmaceutical AB, H2 2016 74

Myocardial Infarction – Pipeline by New World Laboratories, Inc., H2 2016 75

Myocardial Infarction – Pipeline by Novartis AG, H2 2016 76

Myocardial Infarction – Pipeline by NuvOx Pharma LLC, H2 2016 77

Myocardial Infarction – Pipeline by Omeros Corporation, H2 2016 78

Myocardial Infarction – Pipeline by Opsona Therapeutics Limited, H2 2016 79

Myocardial Infarction – Pipeline by Otsuka Holdings Co., Ltd., H2 2016 80

Myocardial Infarction – Pipeline by Pfizer Inc., H2 2016 81

Myocardial Infarction – Pipeline by Pharmathen Pharmaceuticals S.A., H2 2016 82

Myocardial Infarction – Pipeline by Primary Peptides, Inc., H2 2016 83

Myocardial Infarction – Pipeline by Quantum Genomics SA, H2 2016 84

Myocardial Infarction – Pipeline by Quark Pharmaceuticals, Inc., H2 2016 85

Myocardial Infarction – Pipeline by Recardio GmbH, H2 2016 86

Myocardial Infarction – Pipeline by RegeneRx Biopharmaceuticals, Inc., H2 2016 87

Myocardial Infarction – Pipeline by Serodus ASA, H2 2016 88

Myocardial Infarction – Pipeline by Silver Creek Pharmaceuticals, Inc., H2 2016 89

Myocardial Infarction – Pipeline by Stealth BioTherapeutics Inc., H2 2016 90

Myocardial Infarction – Pipeline by Stemedica Cell Technologies, Inc., H2 2016 91

Myocardial Infarction – Pipeline by TaiGen Biotechnology Co., Ltd., H2 2016 92

Myocardial Infarction – Pipeline by Targazyme, Inc., H2 2016 93

Myocardial Infarction – Pipeline by The International Biotechnology Center (IBC) Generium, H2 2016 94

Myocardial Infarction – Pipeline by TiGenix NV, H2 2016 95

Myocardial Infarction – Pipeline by Vicore Pharma AB, H2 2016 96

Myocardial Infarction – Pipeline by XBiotech Inc, H2 2016 97

Myocardial Infarction – Pipeline by Yuyu Pharma, Inc., H2 2016 98

Myocardial Infarction – Pipeline by Zydus Cadila Healthcare Limited, H2 2016 99

Assessment by Monotherapy Products, H2 2016 100

Assessment by Combination Products, H2 2016 101

Number of Products by Stage and Target, H2 2016 103

Number of Products by Stage and Mechanism of Action, H2 2016 108

Number of Products by Stage and Route of Administration, H2 2016 114

Number of Products by Stage and Molecule Type, H2 2016 116

Myocardial Infarction – Dormant Projects, H2 2016 332

Myocardial Infarction – Dormant Projects (Contd..1), H2 2016 333

Myocardial Infarction – Dormant Projects (Contd..2), H2 2016 334

Myocardial Infarction – Dormant Projects (Contd..3), H2 2016 335

Myocardial Infarction – Dormant Projects (Contd..4), H2 2016 336

Myocardial Infarction – Dormant Projects (Contd..5), H2 2016 337

Myocardial Infarction – Dormant Projects (Contd..6), H2 2016 338

Myocardial Infarction – Dormant Projects (Contd..7), H2 2016 339

Myocardial Infarction – Dormant Projects (Contd..8), H2 2016 340

Myocardial Infarction – Discontinued Products, H2 2016 341

List of Figures

List of Figures

Number of Products under Development for Myocardial Infarction, H2 2016 21

Number of Products under Development for Myocardial Infarction – Comparative Analysis, H2 2016 22

Number of Products under Development by Companies, H2 2016 23

Number of Products under Investigation by Universities/Institutes, H2 2016 28

Comparative Analysis by Late Stage Development, H2 2016 30

Comparative Analysis by Clinical Stage Development, H2 2016 31

Comparative Analysis by Early Stage Products, H2 2016 32

Assessment by Monotherapy Products, H2 2016 100

Number of Products by Top 10 Targets, H2 2016 102

Number of Products by Stage and Top 10 Targets, H2 2016 102

Number of Products by Top 10 Mechanism of Actions, H2 2016 107

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 107

Number of Products by Top 10 Routes of Administration, H2 2016 113

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 113

Number of Products by Top 10 Molecule Types, H2 2016 115

Number of Products by Stage and Top 10 Molecule Types, H2 2016 115

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports